BioVie Inc. (NASDAQ:BIVI – Get Free Report)’s share price rose 12% during mid-day trading on Wednesday . The stock traded as high as $1.83 and last traded at $1.77. 285,842 shares were traded during trading, an increase of 28% from the average daily volume of 222,864 shares. The stock had previously closed at $1.58.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioVie in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.
Read Our Latest Research Report on BioVie
BioVie Stock Up 12.0%
BioVie (NASDAQ:BIVI – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.03.
Hedge Funds Weigh In On BioVie
Institutional investors and hedge funds have recently modified their holdings of the business. Prelude Capital Management LLC acquired a new position in BioVie in the 3rd quarter worth about $275,000. Prosperity Wealth Management Inc. purchased a new position in BioVie during the third quarter worth approximately $273,000. DRW Securities LLC acquired a new stake in BioVie in the fourth quarter valued at approximately $149,000. Citadel Advisors LLC acquired a new stake in BioVie in the third quarter valued at approximately $199,000. Finally, Renaissance Technologies LLC increased its position in shares of BioVie by 142.4% in the first quarter. Renaissance Technologies LLC now owns 67,918 shares of the company’s stock valued at $95,000 after buying an additional 39,900 shares in the last quarter. Hedge funds and other institutional investors own 4.59% of the company’s stock.
About BioVie
BioVie Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for chronic liver diseases and associated neurological complications. The company’s research and development efforts center on candidates designed to address serious unmet medical needs in hepatic encephalopathy and other liver‐related disorders. BioVie advances its pipeline through controlled clinical trials and regulatory interactions in North America.
The company’s lead product candidate, BIV201, is undergoing Phase 2 clinical evaluation for the treatment of hepatic encephalopathy, a life‐threatening condition marked by elevated neurotoxins in patients with advanced liver disease.
Featured Stories
- Five stocks we like better than BioVie
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.
